Nano-X Imaging Shares Plunge 17% Amid CFO Change and Q4 Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Should l Buy NNOX?
Source: seekingalpha
- Earnings Miss: Nano-X Imaging reported Q4 2025 revenue of $3.7 million, missing consensus by $0.3 million, leading to a ~17% drop in shares on Monday, potentially marking its worst intraday decline in over two years.
- Surging Net Loss: The company's net loss for Q4 surged approximately 137% year-over-year to $33.4 million, primarily due to a $17.5 million impairment charge from restructuring efforts, indicating a significant deterioration in financial health.
- CFO Transition: Nano-X announced Guy Nathanzon from Valens Semiconductor as the new CFO, replacing Ran Daniel, who will step down on July 31, 2026, after five years, which may impact future financial strategies.
- Outlook Reaffirmed: Despite recording $13 million in revenue for 2025, Nano-X reiterated its full-year revenue outlook of $35 million for 2026, reflecting confidence in future growth, although the timing of system activations will influence revenue growth pace.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NNOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NNOX
Wall Street analysts forecast NNOX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.760
Low
7.00
Averages
7.00
High
7.00
Current: 1.760
Low
7.00
Averages
7.00
High
7.00
About NNOX
Nano-X Imaging Ltd is an Israel-based company that develops a digital X-ray source enabling a cost reduction of imaging systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nano-X Imaging Under Investigation for Possible Securities Violations
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million in Q4 2026, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, indicating challenges in cost control and operational efficiency that may undermine investor confidence moving forward.
- Executive Change Impact: CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's financial management capabilities, potentially affecting shareholder expectations regarding future growth and stability.
- Stock Price Volatility: Following the earnings announcement, Nano-X's stock price plummeted by $0.70, or approximately 25%, from $2.85 on April 17, 2026, reflecting investor anxiety over the company's financial health and possibly triggering further market sell-offs.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Nano-X, and while no lawsuit has been filed yet, the inquiry could have long-term implications for the company's reputation and stock price, necessitating close monitoring by investors.
See More
Investigation Launched into Nano-X Imaging for Securities Fraud
- Financial Loss Disclosure: Nano-X Imaging reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, which included a $17.5 million impairment charge due to restructuring at its Korean chip manufacturing facility, highlighting significant financial strain and operational challenges faced by the company.
- Executive Departure Impact: The announcement of CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's future financial management and strategic direction, potentially undermining investor confidence and exacerbating market uncertainty.
- Stock Price Volatility: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting investor anxiety regarding the company's financial health and a pessimistic outlook on its future performance.
- Legal Investigation Initiated: Wolf Haldenstein Adler Freeman & Herz LLP has launched an investigation into whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could lead to further legal actions and increase the company's legal risks and potential liabilities.
See More
NANO-X IMAGING LTD - NUVIODX TO IMPLEMENT NANOX.ARC SYSTEMS AT CLINICAL LOCATIONS IN SEVERAL STATES
Deployment of Nano Imaging Technology: Nano Imaging Ltd has announced the deployment of its NanoX imaging systems across various clinical sites in multiple states.
Expansion of Clinical Applications: The deployment aims to enhance clinical applications and improve diagnostic capabilities in healthcare settings.
See More
Nano-X Under Investigation Amid Securities Fraud Claims, Stock Plummets
- Severe Financial Loss: Nano-X reported a net loss of $33.4 million for Q4 2025, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, highlighting significant financial pressure and operational challenges faced by the company.
- Executive Departure: CFO Ran Daniel announced his resignation effective July 31, 2026, which may undermine investor confidence in the company's future financial management and exacerbate market uncertainty.
- Stock Price Plunge: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting investor concerns regarding the company's financial health and future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, potentially leading to further legal risks and financial liabilities that could impact the company's reputation and shareholder interests.
See More
Pomerantz Investigates Nano-X for Securities Fraud Claims
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million impairment charge related to restructuring at its Korean chip manufacturing facility, indicating significant challenges in financial management.
- Executive Departure: The announcement of CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's future financial transparency and management stability, potentially impacting investor confidence.
- Stock Price Plunge: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting strong market concerns regarding the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could lead to class action lawsuits and further exacerbate investor anxiety.
See More
Nano-X Imaging Under Investigation for Possible Securities Violations
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, indicating challenges in cost control and operational efficiency that could undermine investor confidence moving forward.
- Executive Departure Impact: CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's financial management capabilities, potentially exacerbating shareholder worries regarding future growth prospects and stability.
- Stock Price Volatility: Following the earnings announcement, Nano-X's stock plummeted approximately 25%, from $2.85 on April 17, 2026, to $2.15 on April 20, 2026, prompting investors to reassess the company's financial health and market position.
- Legal Investigation Initiated: Kirby McInerney LLP is investigating Nano-X for potential violations of federal securities laws, and while no lawsuit has been filed yet, this inquiry could have significant implications for the company's future legal liabilities and market reputation.
See More
Nano-X Imaging Under Investigation for Possible Securities Violations
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million in Q4 2026, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, indicating challenges in cost control and operational efficiency that may undermine investor confidence moving forward.
- Executive Change Impact: CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's financial management capabilities, potentially affecting shareholder expectations regarding future growth and stability.
- Stock Price Volatility: Following the earnings announcement, Nano-X's stock price plummeted by $0.70, or approximately 25%, from $2.85 on April 17, 2026, reflecting investor anxiety over the company's financial health and possibly triggering further market sell-offs.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by Nano-X, and while no lawsuit has been filed yet, the inquiry could have long-term implications for the company's reputation and stock price, necessitating close monitoring by investors.
See More
Investigation Launched into Nano-X Imaging for Securities Fraud
- Financial Loss Disclosure: Nano-X Imaging reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, which included a $17.5 million impairment charge due to restructuring at its Korean chip manufacturing facility, highlighting significant financial strain and operational challenges faced by the company.
- Executive Departure Impact: The announcement of CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's future financial management and strategic direction, potentially undermining investor confidence and exacerbating market uncertainty.
- Stock Price Volatility: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting investor anxiety regarding the company's financial health and a pessimistic outlook on its future performance.
- Legal Investigation Initiated: Wolf Haldenstein Adler Freeman & Herz LLP has launched an investigation into whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could lead to further legal actions and increase the company's legal risks and potential liabilities.
See More
NANO-X IMAGING LTD - NUVIODX TO IMPLEMENT NANOX.ARC SYSTEMS AT CLINICAL LOCATIONS IN SEVERAL STATES
Deployment of Nano Imaging Technology: Nano Imaging Ltd has announced the deployment of its NanoX imaging systems across various clinical sites in multiple states.
Expansion of Clinical Applications: The deployment aims to enhance clinical applications and improve diagnostic capabilities in healthcare settings.
See More
Nano-X Under Investigation Amid Securities Fraud Claims, Stock Plummets
- Severe Financial Loss: Nano-X reported a net loss of $33.4 million for Q4 2025, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, highlighting significant financial pressure and operational challenges faced by the company.
- Executive Departure: CFO Ran Daniel announced his resignation effective July 31, 2026, which may undermine investor confidence in the company's future financial management and exacerbate market uncertainty.
- Stock Price Plunge: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting investor concerns regarding the company's financial health and future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, potentially leading to further legal risks and financial liabilities that could impact the company's reputation and shareholder interests.
See More
Pomerantz Investigates Nano-X for Securities Fraud Claims
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025 in its April 20, 2026 press release, primarily due to a $17.5 million impairment charge related to restructuring at its Korean chip manufacturing facility, indicating significant challenges in financial management.
- Executive Departure: The announcement of CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's future financial transparency and management stability, potentially impacting investor confidence.
- Stock Price Plunge: Following the earnings report, Nano-X's stock price fell by $0.70, or 24.39%, closing at $2.16 per share, reflecting strong market concerns regarding the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Nano-X and its executives engaged in securities fraud or other unlawful business practices, which could lead to class action lawsuits and further exacerbate investor anxiety.
See More
Nano-X Imaging Under Investigation for Possible Securities Violations
- Financial Loss Disclosure: Nano-X reported a net loss of $33.4 million for Q4 2025, primarily due to a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility, indicating challenges in cost control and operational efficiency that could undermine investor confidence moving forward.
- Executive Departure Impact: CFO Ran Daniel's resignation effective July 31, 2026, raises concerns about the company's financial management capabilities, potentially exacerbating shareholder worries regarding future growth prospects and stability.
- Stock Price Volatility: Following the earnings announcement, Nano-X's stock plummeted approximately 25%, from $2.85 on April 17, 2026, to $2.15 on April 20, 2026, prompting investors to reassess the company's financial health and market position.
- Legal Investigation Initiated: Kirby McInerney LLP is investigating Nano-X for potential violations of federal securities laws, and while no lawsuit has been filed yet, this inquiry could have significant implications for the company's future legal liabilities and market reputation.
See More
